Royal Canin has launched two new skincare diets.
'Hypoallergenic Wet' is a wet adaptation of its 'Hypoallergenic' range of diets, providing variety for the nutritional management of dogs with adverse food reactions. 'Anallergenic' dry food is for the dietary management of dogs with even the most severe dietary allergy.
'Hypoallergenic Wet' contains soy protein hydrolysate, so it can either be fed as a complete diet or interchanged and used as an addition to Hypoallergenic, Hypoallergenic Moderate Calorie or Hypoallergenic Small Dog. The wet food, available in a 400g can, can be recommended for short term feeding (for an elimination diet strategy) or for the lifelong nutritional management of dogs with adverse food reactions. Royal Canin says it is designed to be highly digestible through its low molecular weight peptides and is also appropriate for the dietary support of dogs with inflammatory bowel disease, chronic diarrhoea and Exocrine Pancreatic Insufficiency (EPI).
'Anallergenic' follows in the footsteps of Hypoallergenic but goes further - offering both hydrolysed proteins and a pure carbohydrate source, to which exposure is limited and therefore allergy would be rare. The diet comprises a unique protein source composed exclusively of free amino acids and very low molecular weight oligopeptides. Much like the Hypoallergenic range, Anallergenic is also formulated with essential fatty acids to help support skin health and a complex of nutrients to help maintain the barrier effect of the skin.
The fully balanced diet - suitable for the nutritional support of adult dogs either short or long-term - has proven results with 100% of dogs in a Royal Canin study showing significant improvement in their skin condition.
Gudi Stuttard BVSc MRCVS, one of Royal Canin's Veterinary Support Managers, said: "These two new products join our well-established 'Hypoallergenic' range, as well as our recently launched 'Skin Care' diets - for the nutritional management of dogs with dermatosis unrelated to food intolerance or allergy.
"By building on our portfolio of veterinary skin care diets, we aim to further strengthen our DermAlliance campaign, which is dedicated to assisting in the improvement of skin care knowledge in general veterinary practice."
Please visit www.royalcanin.co.uk for more information.
MSD's push is being driven by the rising number of cases of Leishmaniasis cases in the UK, including the first report earlier this year of dog-to-dog transmission of the disease.
Caroline Darouj, Product Manager at MSD Animal Health said: "Whilst accurate statistics on the number of cases seen in UK practices are not available, the VMD has reported an annual increase in the number of leishmaniasis treatments imported since records started in 2006.
"Based on applications for Special Import Certificates for Milteforan and Glucantime, there were 27 times as many cases treated in 2018 (439) compared to 2006 (16)*.
"Leishmaniasis is proving to be a significant threat to travelling dogs, a situation that has been widely reported in the vet press, so LetiFend will offer veterinary practices and dog owners throughout the UK reassurance. A single dose primary course given four weeks before travel makes it ideal for non-regular travelers."
Letifend is indicated to reduce the risk of developing active infection and/or clinical disease after exposure to L. infantum from 28 days post vaccination1,2. It offers protection for 365 days after a single annual dose. The company says it has excellent tolerability shown in a wide range of breeds and ages, and in field trials in areas at high risk of infection had an efficacy rate of 72%4.
LetiFend is a non-adjuvanted vaccine which MSD says ensures a targeted immune response with a high level of safety.
MSD says a dog vaccinated with LetiFend is at 9.8 times less risk of presenting clinical signs, at 3.5 times less risk of presenting parasites, and thus at 5 times less risk of developing clinical leishmaniasis1. It can be applied from six months of age via subcutaneous administration.
For further information contact your MSD Animal Health account manager.
References
*Information from VMD following a Freedom of Information Act request.
Veterinary surgeon Niall Taylor has signed a deal worth a reported £100 to become the new face of VetSurgeon.org.
As part of the deal, Niall will appear in magazine adverts for the community website in Veterinary Practice magazine. VetSurgeon publishers have so far not confirmed rumours that he will also be appearing on billboards alongside the M4, M1 and M25 motorways, and in TV ads after Coronation Street.
Niall said: "I'm donating my earnings from this contract to support our practice manager, Alyson Gough, who'll be running the London Marathon to raise money for SENSE, a charity which supports deafblind people. If any of my colleagues would like to join me in supporting this important cause, you can do so at: http://www.justgiving.com/Alyson-Gough
Niall replaces the outgoing face of VetSurgeon, Gillian Mostyn MRCVS. She said: "I've had a wonderful year. Being the face of VetSurgeon has opened so many doors for me. I wish Niall all the very best".
The RCVS is encouraging veterinary surgeons, veterinary nurses and other members of the practice team to respond to a government consultation on changing the law to introduce English language testing for veterinary surgeons who have qualified from elsewhere in the European Union.
Under the proposals outlined in the consultation by the Department for Environment, Food and Rural Affairs (Defra), the test would apply before an individual joined the Register and only where the RCVS had ‘serious and concrete doubts’ about their English language abilities. The plan to consult on this issue had been welcomed by RCVS Council at its June 2015 meeting.
Every year, around half of all new veterinary surgeon registrants are from outside the UK, the majority from other EU or European Economic Area (EEA) countries. These individuals fall within the scope of the Mutual Recognition of Professional Qualifications (MRPQ) Directive, which applies to all EU nationals wishing to practise in a regulated profession in another member state.
Last year, a revised version of the MRPQ Directive came into force, which made a number of changes, including clarifying and reinforcing the role of competent authorities such as the RCVS. One of these changes is that language testing is expressly permitted, but only where serious concerns have been identified.
Gordon Hockey, RCVS Registrar, said: “Under the current legislation the College is not able to bar someone from joining the Register, and therefore practising, on the basis of language ability, even where we may have serious concerns.
“I would encourage all veterinary surgeons, veterinary nurses and other members of the practice team to engage with this consultation and consider whether the College should have the right to impose a language test where it has serious doubts, more in line with medical doctors, and the form such testing would take.”
Under the proposals, applicants would be asked a series of questions concerning their language qualifications, experience and general ability to use the English language before registering. Depending on how they answer the questions they may then have to pass a language test before registering, or delay their application while they improve their language skills.
The consultation results will inform the College’s work with Defra to determine whether to proceed with implementation and, if so, to develop the most appropriate system of language testing. The College would implement language testing for veterinary nurses in parallel with any changes for veterinary surgeons.
Those who wish to take part in the consultation can do so at https://consult.defra.gov.uk/animal-health-and-welfare/vet_language_controls. The deadline for responses is Wednesday 30 September 2015.
The session will cover the indications and case selection for surgery, alongside the surgical steps for cholecystectomy and cholecystoduodenostomy.
Alasdair will discuss:
The session is aimed at veterinary surgeons and is intended to help attendees refresh their knowledge and build confidence in dealing with biliary tract surgery in small animals.
The session costs £50.
https://vet-learn.com/product/biliary-mucocoele-and-other-biliary-tract-surgery
The group, which was convened by Boehringer Ingelheim, made its recommendation in a poster published at the National Mastitis Council meeting in Arizona1, prior to the launch of Boehringer's new teat sealant, Ubroseal.
The poster added that those animals that are likely to be infected need to receive antibiotic dry cow therapy (ADCT) in addition to a teat sealant.
Boehringer says various studies have shown that using an ITS reduces the risk of new intramammary infections and reduces the risk of clinical mastitis after calving, pointing to a meta-analysis of published papers which showed a 25% reduced risk of new infections and a 29% reduced risk of clinical mastitis for cows receiving ITS plus ADCT compared with ADCT alone
Boehringer’s veterinary adviser, Kath Aplin said: "Against the backdrop of targets from RUMA to reduce antibiotic use in the dairy sector3, adopting ITS for all cows could significantly reduce the need for antibiotics. An increase in the use of ITS is included in the dairy sector targets.
"We estimate that, currently, around 29% of the national herd is dried off without an ITS, so there is huge room for growth4."
Kath added: "With a 300-cow US study showing that a week after drying off, 47% of teats had still not formed a keratin plug5 and a New Zealand study showing that one in 20 cows had teats that remained open for 60 days6, it is clear to see that delayed teat closure is a very real problem in many herds. Teats remaining open after dry off make the udder highly susceptible to infection and delayed teat closure exacerbates the risk of acquiring an intramammary infection post-dry off4."
The expert group also recommended developing a herd plan, classifying herds as low risk or high risk and having a different approach to each.
High risk herds will have had a bulk SCC of >250,000 cell/ml in at least two of the last six months, they may also have a problem with Strep. agalactiae or could be experiencing an unavoidable risk period (a new building for example).
The priority should be to improve udder health management during both the lactation and dry period and any decision to abandon ADCT should be made with care and a full risk assessment.
The group said that in reality, it may be prudent to continue blanket ADCT until udder health has improved.
The group’s recommendations for low risk herds (<250,000 cells/ml in four out of the last six months) were to actively strive towards selective ADCT, supported by ITS for all cows.
The full recommendations are published in the proceedings of the NMC1 or can be obtained from your local Boehringer Ingelheim representative.
Kath said: "It has long been established that the mammary gland is highly susceptible to infection in the dry period and that the majority of clinical mastitis in early lactation is picked up during the dry period.
"Moving towards selective ADCT may not be appropriate immediately for all producers. However, the use of ITS for all cows on all farms will reduce new infection rates, assisting in the drive towards improved udder health and reduced antibiotic use."
Photo: Curious cattle on farmland in Cornwall UK. Shutterstock/Shzphoto
The Group has trained almost 100 of its staff as 'mental health first aiders'.
Michelle O’Connor, the Linnaeus Group’s people and culture director (pictured right), said: "Veterinarians are three to four times more likely to die by suicide than workers from any other industry.
"Because of this alarming statistic, we have put wellbeing at the very forefront of our strategy and have so far trained nearly 100 mental health first aiders within the group.
The Linnaeus volunteers, who are taken from both office and clinical roles, have all attended a training course run by Mental Health First Aid England (MHFA) to acquire the skills to support their own and others’ wellbeing.
The MHFA course trains people to identify the signs of mental ill health, to break down the stigma and barriers surrounding mental health and listen to colleagues in a non-judgemental way, and to help direct those suffering from issues to the support and guidance that’s available.
Michelle added: "We realise training on how to spot signs of a crisis and become a mental health first aider alone does not address the prevailing stigma around mental health in the workplace.
"So, in addition, we are developing a culture where support and conversations about mental health are normalised, so that colleagues feel able to reach out for the important support they need."
Vikaly is indicated for the nutritional and medical management of chronic kidney disease in adult and senior cats with proteinuria, from IRIS stage 2.
The new diet delivers the same therapeutic dosage as benazepril tablets (0.5–1 mg/kg bodyweight/day).
Nutrition-wise, Vikaly is low phosphorus (0.5% as fed), has reduced protein (30% as fed), contains omega-3 fatty acids (1.2%, including 0.6% EPA & DHA) and offers high metabolisable energy (416 kcal/100g).
Virbac highlights data showing that CKD remains the leading cause of mortality in cats over five years old and affects up to 40% of feline patients over the age of ten1,2.
The company says administering daily treatment is recognised as a major issue for CKD cat owners with 45% of owners not administering treatment daily as they should and 51% of owners citing administration difficulties as the reason why3.
This new product eliminates the need to administer medication separately, which could completely transform treatment compliance, removing the risk of missed doses and reducing stress for both cats and their owners.
Virbac says that due to the pharmacokinetic profile of benazepril, which is incorporated into the kibble, at an equivalent dose Vikaly displays greater ACE inhibition than benazepril tablets4.
The rate of food consumption also does not affect plasma Benazeprilat levels, ensuring consistent treatment efficacy regardless of the cat’s feeding behaviour5.
Virbac says that in practice, this means that even if the cat being treated consumes less than 50% of their daily ration, efficacy is maintained with ACE activity similar to that of benazepril tablets.
Benazepril has a wide therapeutic margin, tolerated to 20x the minimum effective dose (10mg/kg) for 52 weeks, with the first signs of toxicity being reduced erythrocytes counts & ovary/oviduct weights6.
Virbac says that with Vikaly, these levels cannot be reached because the active ingredient is contained in food, which would require a cat to consume more than 10 times their daily ration.
Vikaly is presented in a 1.5kg bag, which equates to a 30 day supply for a 4.5kg cat with normal bodyweight.
It can be fed alongside wet food, providing that the cat consumes at least 50% of their daily ration before being given the wet food.
The daily ration can also be administered in several smaller meals throughout the day, to accommodate the individual preferences of the cat and to promote consistent food intake.
Vikaly is a prescription diet.
The students are being given the chance to treat cats, dogs and rabbits coming into the RSPCA centre under the supervision of its resident veterinary surgeon, Joanne Henstock.
The placement offers them valuable skills in dealing with animals which have received little or no veterinary care in the past and often arrive at the shelter in an extremely poor condition.
Ella Carpenter, RSPCA Animal Centre Manager, said: "The students are familiar with seeing pets which have been well cared for by their owners and it can be shocking for them to witness the state in which some of the animals arrive at our shelter.
"In particular, they see the, often life-threatening, impact it can have on an animal when it hasn’t received care considered to be fundamental veterinary medicine, such as flea or worming treatments.
"We commonly see animals that arrive with little or no medical history, so they can practice a back to basics, 'treat what we see', approach. And they learn about the challenges we face in providing the best possible care for large numbers of animals, many with complex medical needs, while working within the finite resources of a charity which relies entirely on public donations."
Malcolm Cobb, Professor of Comparative Veterinary Medicine and Deputy Head of the School of Veterinary Medicine and Science, said: "We are really excited to be working with the RSPCA at Radcliffe. There is a very large and varied case load for our students to assist with, learn from and help to manage, including some cases of neglect which they might not see elsewhere, and which can represent a significant clinical challenge."
Photo: Jo Henstock (Associate Vet RSPCA), Bramble the Beagle, Sophie Isaacs (Final Year Vet Student), © The University of Nottingham
The RCVS has advised that veterinary surgeons should delegate Schedule 3 work to veterinary nurse students only during students' training, following a series of queries from employers about such students locuming.
Veterinary surgeons have dispensations under Schedule 3 of the Veterinary Surgeons Act to delegate to student veterinary nurses in the course of their training, so that students can learn how to give medical treatments to animals.
Crucially, these dispensations apply only when the student is working as a student in their approved training practice or on a placement organised by their university, and is under the supervision of qualified staff.
These dispensations do not apply to any extra-curricula activity so, if working as locums, they are legally classified as unqualified lay staff
The RCVS is concerned that locum agencies do not always appear to know this and are placing locums in their capacity as students, or even "senior students." This has the potential to mislead employers and the students concerned, and result in illegal practice.
Liz Branscombe, Chairman of the RCVS Veterinary Nurses Council said: "We know that student VNs, especially those on university courses, often undertake locum work to supplement their earnings. However, beyond the training practice which employs them, or in a placement organised by their university, they can only carry out tasks that may be expected of an unqualified staff member, and cannot legally undertake Schedule 3 work."
Practices may check the details of a student VN directly with the RCVS or with the student's college. If you notice an agency promoting student VN locums, please contact the RCVS so that we can provide guidance.
The RVC has published the results of a study which showed that dogs treated with pimobendan at the preclinical stage of mitral valve disease (MVD) remained asymptomatic for an average 15 months longer and lived for significantly longer than the placebo group.
The EPIC study (Evaluation of Pimobendan In Cardiomegaly), published open access in the Journal of Veterinary Internal Medicine1, is the largest prospective veterinary cardiology study carried out to date. The authors say that the quality of the data it produced rivals that of human clinical trials.
The study was double-blinded, placebo-controlled and randomised. It took seven years to complete and involved 360 dogs across 11 countries in four continents.
To qualify for enrolment in the study, dogs had to be 6 years of age or older, have a body weight ≥4.1 and ≤15 kg, have a characteristic systolic heart murmur of moderate to high intensity (≥ grade 3/6) with maximal intensity over the mitral area, have echocardiographic evidence of advanced MMVD defined as characteristic valvular lesions of the mitral valve apparatus, mitral regurgitation on the colour Doppler echocardiogram, and have echocardiographic evidence of left atrial and left ventricular dilatation, defined as a left atrial-to-aortic root ratio ≥ 1.6 and body weight normalized left ventricular internal diameter in diastole ≥ 1.7, in addition to radiographic evidence of cardiomegaly (vertebral heart sum > 10.5)
In fact, the study was terminated early following an interim analysis as the evidence was considered conclusive and it was deemed unethical to continue to withhold treatment from the placebo group.
Adrian Boswood, Professor of Veterinary Cardiology at the RVC (pictured above right), led the research. He said: "Thanks to the EPIC study results, vets no longer have to adopt a 'watch and wait' approach to suspected preclinical cases of MVD. When a typical mitral valve murmur is detected, vets should now investigate further to look for cardiac enlargement. If demonstrated, this suggests the patient will probably benefit from treatment with pimobendan before the onset of clinical signs.
"It's great that as a trusted treatment, pimobendan has a wealth of safety data behind it in addition to that gleaned from the EPIC study, which can help support vets when prescribing it in this new way."
Adrian added: "As far as evidence-based medicine goes, this is about as good as it gets. The size and design of the study places it in the top-tier. The study was designed and run by an independent team of investigators and sponsored by Boehringer Ingelheim. We, as lead investigators, had the right to publish the results regardless of the outcome. This makes EPIC very special indeed."
In light of the findings, Adrian says vets should now consider testing early for signs of preclinical MVD, and in dogs with cardiomegaly secondary to preclinical MVD, consider the use of pimobendan to delay the onset of congestive heart failure and extend the asymptomatic period.
To read more about the EPIC study and results, visit www.rvc.ac.uk
Reference
For the studies, the owners of 68 dogs treated with Librela and 44 cats treated with Solensia answered 22 questions in the case of dogs and 20 questions in the case of cats on VetMetrica, a digital HRQL instrument.
With a scale of 0-6, cats were rated on vitality, comfort and emotional wellbeing, and dogs on energetic/enthusiastic, happy/content, active/comfortable and calm/relaxed, over a period of 70 days.
The studies concluded that both Librela and Solensia produced a significant improvement in HRQL within 14 days of initial treatment, which was the first time the QOL impact was measured.
The improvement was maintained for the duration of the study.
Jacky Reid, BVMS PhD DVA, CEO of NewMetrica, now part of Zoetis, said: “Assessing and understanding how OA-related pain impacts emotional and physical well-being in particular circumstances, broadens the perspective in relation to pain management.
“HRQL measurements are not generally implemented in veterinary science at this time, so it’s exciting to see how it’s proving effective at adding value to existing functional measures.
"Particularly, helping us understand how pain management impacts the physical and emotional wellbeing of animals and will ultimately boost pet owner confidence.”
Oya Canbas, Zoetis UK General Manager, explained: “With an ever-growing bond between humans and animals, and pets leading longer lives, pet owners are more motivated than ever to support their pet’s wellbeing.
"However, not all are aware of the negative impacts of chronic disease, with signs of OA pain often mistaken as ‘normal’ signs of aging.
"This is why we need to increase awareness, to tackle under-diagnosis of OA pain.
"Common medications used to treat cases of OA pain that are diagnosed are often Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
"While effective, these can have limitations, such as for middle aged to senior pets which have other diseases, requiring multiple medications.
"Some will not tolerate NSAIDs, and not all pets respond to NSAID therapy.
"So, expanding prescription choices is a privilege.”
EthyCalm is sprayed directly on the skin, or, for more fractious patients, can be applied with a swab.
Invicta says that unlike other products the effect is instant and EthyCalm leaves no residue on the skin surface.
The improved product, EthyCalm Plus, contains 50% more product (good for over 100 applications) and incorporates a new 'on-off' switch for easier application. It is also now packed in a 'no-roll' case to protect from damage.
Rob Watkins, Managing Director of Invicta, said: "EthyCalm has been an incredibly popular product with nurses and vets. As a small company we always listen to our customers and have taken the opportunity to incorporate suggestions for improvement. The result is EthyCalm Plus which offers significant enhancement over the original product".
EthyCalm Plus is available from veterinary wholesalers and for a limited time the price has been held at £25 each.
The new product, which is for the management of any condition where eye health is supported by providing additional moisture or lubrication, is suitable for dogs, cats, horses, rabbits and other animals.
Oculeze contains glycerine (0.8%), Aloe vera, chamomile and propolis extract, the latter of which contains polyphenols which Millpledge says have been shown to support corneal health by multiple mechanisms of action including modulation of the tear film and a reduction in inflammation, apoptosis and oxidative stress1.
Millpledge says Oculeze lasts longer on the ocular surface than non-lipid lubricants2 because it evaporates more slowly3.
This prolonged action means fewer administrations, which should help client compliance.
Oculeze comes in two sizes - a 10 millilitre bottle and a pack of ten resealable 0.6 millilitre vials, suitable for short term use and travel.
The 10ml bottle includes a filter, preserving sterility for up to three months after opening.
Oculeze is available direct from Millpledge or from your usual wholesaler.
https://millpledge.com/shop/oculeze
sales@millpledge.com
The book guides the reader through the evolutionary background of dogs and cats and explains how inherited diseases and deformities associated with certain breeds can cause breathing problems, heart disease, skin problems and back problems.
The book concludes with practical advice to help owners buy a healthy puppy or kitten and to avoid the risk of supporting puppy farms.
Emma said: "I’ve been campaigning on this issue for twenty years and, if anything the conformational issues and inherited disease problems in dogs and cats, are getting worse with some breeders striving for ever more extreme body shapes.
"Selecting a pet with inherited defects can cost thousands in vet bills and cause anguish for family members. It also creates a relinquishment problem for animal shelters as they have to take in abandoned pets with health problems.
"While awareness is certainly increasing, too often prospective pet owners are still unaware of the health implications of the pet they are buying and it is difficult for my veterinary colleagues to criticise the choice of a client’s puppy or kitten once it has been bought. All too often though they are left to pick up the pieces."
Emma added: "Education is the key. It is vital that prospective owners understand why different body shapes could be detrimental to health and how far removed from nature some of our breeds now are. If we can encourage them to stop choosing the quirky extremes in some breeds, demand for them will soon fall. My message is simple – we should all prioritise health and temperament way above what animals look like.
"I hope that responsible prospective pet owners will find Picking a Pedigree? an enlightening read and that it will inform their choice of a new family member. I also hope that it will be a useful resource for vets and nurses to be able to recommend to reinforce their pre-purchase advice."
The new bottle size will last approximately 100 days when treating an average sized cat of 4 kg.
Amy Scott, brand manager for Semintra said: "The new 100 ml bottle size will ensure that Semintra is even more convenient for owners, whilst facilitating long-term compliance that fits in well with recommended recheck intervals for CKD."
Cats with CKD have an overactive renin-angiotensin-aldosterone system (RAAS), which can lead to proteinuria and further progression of kidney disease. Semintra contains the active ingredient telmisartan – the only angiotensin receptor blocker (ARB) licensed for use in veterinary medicine. Boehringer says it provides targeted, long-lasting suppression of the RAAS1.
Semintra is a once daily oral liquid. Now available in both 30 ml and 100 ml bottle sizes, it has a six month shelf life after opening.
For further information on Semintra visit www.boehringer-academy.co.uk or contact your local Boehringer Ingelheim territory manager.
'Potential role of veterinary flea products in widespread pesticide contamination of English rivers1, was carried out by Professor Dave Goulson and Rosemary Perkins MRCVS from the University of Sussex and co-authored by Martin (pictured right) and Wayne Civil from the Environment Agency.
For the study, they looked at 3,861 samples taken from 20 rivers around the UK between 2016 and 2018. Fipronil was detected in 98% of the samples and imidacloprid in 66%.
Currently, there are no environmental quality standards for fipronil or the compounds it breaks down into (fipronil sulfone or fipronil sulfide) or for imidacloprid in British surface waters.
The authors therefore used the acute and chronic toxicity limits for fipronil from a report from the Department of Environmental Toxicology at the University of California Davis2, and from Morissey et al (2015)3 for imidacloprid.
They found that the average fipronil concentration across the rivers sampled by the Environment Agency exceeded chronic safety thresholds five-fold. The overall pollution levels in English rivers indicate that fipronil and its toxic breakdown products pose a high risk to aquatic ecosystems.
While, in most rivers, imidacloprid was found to pose a moderate risk, in seven out of the 20 rivers sampled there was a high environmental risk.
The paper, published in Science of the Total Environment, noted that the highest levels of pollution were found immediately downstream of wastewater treatment works, which the authors say supports the hypothesis that significant quantities of pesticide may be passing from treated pets to the environment via household drains.
Professor Dave Goulson said “Fipronil and imidacloprid are both highly toxic to all insects and other aquatic invertebrates. Studies have shown both pesticides to be associated with declines in the abundance of aquatic invertebrate communities. The finding that our rivers are routinely and chronically contaminated with both of these chemicals and mixtures of their toxic breakdown products is deeply troubling.”
Bathing of pets treated with spot-on fipronil flea products has been confirmed as a potentially important route to waterways for fipronil via sewers. The washing of hands, pet bedding or other surfaces that have come into contact with treated pets are potential additional pathways for entry to sewers.
Rosemary said: “We’ve identified a number of steps that can be taken to minimise or avoid environmental harm from pet flea and/or tick treatments. These range from introducing stricter prescription-only regulations, to considering a more judicious and risk-based approach to the control of parasites in pets, for example by moving away from blanket year-round prophylactic use."
Martin said: "The profession urgently needs to adopt ‘responsible use of parasiticides’ similar to the way it is adopting responsible use of antimicrobials. The VMD needs to strengthen the environmental assessment of pet pesticide products in the authorisation process, and they are currently considering this issue. The VMD should also collate and publish annual sales figures for these pesticides as they do for antimicrobials."
He added: "My veterinary hospital has never had a ‘pet health plan’ to provide year round flea products, because we believe that year-round, intensive treatment for almost all dogs and cats does not constitute responsible use of such powerful pesticides."
Morrissey, C.A., et al., 2015. Neonicotinoid contamination of global surface waters and associated risk to aquatic invertebrates: a review. Environ. Int. 74, 291–303. https://doi.org/10.1016/j.envint.2014.10.024.
Elanco Animal Health has announced that there have been extensions to the withdrawal periods for Dectomax (doramectin) 10 mg/ml Solution for Injection and Micotil (tilmicosin) 300 mg/ml Solution for Injection.
For Dectomax injectable, meat withdrawal for cattle and sheep will be extended to 70 days and pigs to 77 days. For Micotil, sheep milk withdrawal will be extended to 18 days and milk from cows during the dry period or from pregnant heifers should not be used for human consumption until 36 days after calving.
Elanco is reminding veterinary surgeons and SQPs that they may continue to prescribe according to the current label but it is good practice to implement revised withdrawal periods. The company is also taking this opportunity to highlight the importance of getting into the habit of double-checking withdrawal periods when administering drugs, because they do change from time to time in the light of new knowledge.
Mark, who graduated from Cambridge University in 1997, has a broad interest in internal medicine but particularly enjoys the challenges posed by gastrointestinal, endocrine, haematology and renal medicine.
He has a PhD in Neuroscience at the University of Cambridge and after completing his PhD he took a residency in Small Animal Medicine at Cambridge, followed by four years in a private specialist practice in the south of England.
Mark was then appointed Clinical Associate Professor in Small Animal Internal Medicine at the Nottingham Veterinary School, where he was responsible for running the final year medicine rotation along with lecturing to all years of the veterinary course.
He was also in charge of the school’s small animal intern and residency programmes in addition to supervising both undergraduate and post-graduate research students.
Mark has also been involved in national and international investigations into canine breed-related diseases such as canine cancer, canine and feline haematology, canine endocrine disease and the development of novel non-invasive biomarkers to help diagnose both simple and complex medical diseases.
Outside work, Mark is a seven-guitar-owning-musician, a race-winning cyclist and a keen runner with a personal best of one hour twenty five minutes for a half marathon. What a relief for the rest of us mere mortals to hear there's something he's rubbish at: he says he swims 'like a brick'.
Mark said: "I’m excited to be joining the outstanding team at Willows who deliver such exceptional care to pets and their owners and such an outstanding service to the referring veterinary surgeons.
"It is a wonderful opportunity for me and I’m really looking forward to making my own contribution to their continued success."
To enter the competition, VetSurgeon members just needed to post a 'top tip' that could in any way make life easier, quicker, better or happier for a colleague.
Making use of the new feature on VetSurgeon.org where members can click a link marked 'thank you' to show their appreciation of something useful shared by someone else, VetSurgeon offered five £50 Amazon Vouchers for the most thanked tips shared before the end of November.
The winners are:
Mark Rowland for his tip that Mikki Muzzles make great anaesthesia masks for guinea pigs.
Emma Robinson for her solution to the problem of opening a new bottle "that has one of those annoying little metal caps".
Kate Richardson for her tip, which was to use an elastic band to 'tie' your et tubes in.
Julie Innes for her suggestion to use an elastic/ Velcro back support wrap from the Pound Shop when doing hip scores.
Gillian Mostyn for things you can do with a latex glove.
The RCVS Disciplinary Committee has agreed to adjourn multiple charges against an Essex-based veterinary surgeon who qualified in 1969, following his undertakings firstly to request removal from the RCVS Register and secondly never apply to be restored to it.
At the hearing, which had originally been listed for seven days, Geoffrey Raymond Oliver, 68, was charged with serious professional misconduct over allegations of his inadequate treatment of two dogs and a cat (belonging to three different clients) between 2010 and 2012; inadequate record keeping; failures to deal honestly or properly with his clients; and, failure to heed advice from the RCVS Preliminary Investigation Committee about the importance of proper communication between veterinary surgeons and their clients.
However, before the Committee heard evidence on any aspect of these charges, Mr Oliver lodged his application for adjournment. The Committee therefore made no findings on the charges, and emphasised they had neither been proved against, nor admitted by, him.
The Committee noted that there had been no adverse findings against Mr Oliver during his professional career, that his practice was now closed and that he had no intention of returning to practise in the future. Should he subsequently apply to be restored to the Register, the Committee would resume its consideration of the charges, along with his breach of the undertaking.
The Committee was advised that none of the complainants in the case - which could have incurred considerable time and costs - dissented from the proposed course of action.
Speaking on behalf of the Disciplinary Committee, its Chairman, Professor Peter Lees, said: "The Committee has concluded that no useful purpose would be served were it to insist on a full hearing [and it] would be a disproportionate waste of...resources [to do so]. The Committee is satisfied that [granting the adjournment application] protects the welfare of animals and...is in the public interest."
The Committee then accepted Mr Oliver's undertakings, including the removal of his name from the Register with immediate effect.
Professor Lees added: "So that he is in no doubt about the matter, the Committee reminds [Mr Oliver] that, when referring clients of his former practice elsewhere, he should be careful to avoid giving them any advice about the diagnosis or treatment of their animals."
The charity launched the 'Cat Friendly Clinic' accreditation scheme in 2012, in order to raise standards and reduce the stress experienced by cats (and consequently their owners) when visiting clinics.
In order to be accredited as a Cat Friendly Clinic, a clinic must not only meet high standards of cat care in terms of facilities and equipment, but staff must also demonstrate an understanding of the needs and behaviour of cats and put in place measures to ensure that visits to the clinic are more cat-friendly.
In the six years since its inception, the scheme has become a well-recognised standard in feline veterinary care, with accredited clinics all over the world.
The Classic Animal Hospital in South Korea (wow, see the architects' photos here), was founded in September 2017 and consists of three vets, eight nurses and three receptionists. Open 24 hours a day, 365 days a year, the clinic's goal is to "provide outstanding veterinary care using the most advanced medical techniques and equipment in an environment that is both comfortable and welcoming for owners and their loved companions’. Currently, about 30% of the clinic’s clients are cats, and this percentage is continuing to grow.
Park Sungwon, owner of the clinic and Chief of Surgery, said: "Since more and more Koreans are having cats as their companion animals, there is growing interest in the Cat Friendly Clinic programme. So many veterinarians who have just started or want to start their own clinic share information about becoming a Cat Friendly Clinic. I also found out about the Cat Friendly Clinic scheme on the vet internet community. When I decided to open my clinic, I planned to become a Cat Friendly Clinic. So I took ISFM’s requirements into consideration when I designed my clinic."
When asked what cat owners think of the clinic’s Cat Friendly status, Park said: "They are very satisfied with our separated, quiet, cat-only waiting area and large hospitalisation facilities. They think that their cats definitely feel more comfortable at my clinic than they feel at other clinics in my town."
Sarah Endersby, International Cat Care’s Veterinary Development Manager, said: "We are delighted to have accredited the 1000th Cat Friendly Clinic. It is fabulous to know that many veterinary clinics around the world are thinking about how they can make feline visits less stressful, benefitting not only the cats themselves, but their owners and the veterinary team. We have many clinics looking to become a Cat Friendly Clinic, so the community is growing quickly - hopefully we will be welcoming the 2000th clinic in the not too distant future!"
To find out more about the Cat Friendly Clinic scheme, visit catfriendlyclinic.org.
The scheme is supported by six official partners: Boehringer Ingelheim, Ceva, Elanco, Idexx, Merial and Royal Canin.
Virbac points to research showing that MCTs are the most common form of skin cancer in dogs, accounting for up to 21% of skin cancer cases1.
This, says the company, means that understanding the challenges surrounding mast cell tumour diagnosis, work up (including the various prognostic panels) and treatment selection for mast cell tumour cases is vital.
The session, entitled ‘Fundamentals of Mast Cell Tumour Management’, will conclude with a review of Stelfonta, walking through cases and how to get the best results.
Dr Neil Mottram MRCVS, Technical Product Manager at Virbac said: "We know that vets are facing webinar fatigue.
"We therefore hope that this brand new style of online learning on one of the most common canine cancers will be more engaging, whilst still delivering high quality CPD."
To register for the live event, visit: https://tinyurl.com/mct-masterclass
For more information, speak to your Virbac Territory Manager, or visit vet-uk.virbac.com/stelfonta
Royal Canin has announced that it will be launching Multifunction, a new range of veterinary diets designed for cats and dogs experiencing - or at risk of - multiple health conditions.
According to the company, 35% of cats and dogs meet this description1 and it can be difficult for veterinary surgeons and nurses to recommend a diet which meets all their needs when one diet can't address multiple nutritional priorities.
Officially being launched at BSAVA, Multifunction diets are designed to provide an option for the nutritional management of cats and dogs with more than one condition, thereby eliminating the need to decide which of two conditions take precedence when developing a nutritional assessment for patients.
The company says that the new diets have been developed by combining existing Veterinary Diet formulae. The range includes:
Marianne Lomberg, Veterinary Marketing Manager said: "As a company, one of the things we are proud of is looking at the pet as a whole, rather than just a clinical condition on legs. For this reason we combine the features of our standard veterinary diets to provide support for other issues that a pet may develop. For example, our Urinary Moderate Calorie diet is lower in calories than standard diets in order to help prevent weight gain in animals predisposed to obesity as a result of living indoors or being neutered. However, until now, we have not been able to provide vets with a diet for a pet that has already been diagnosed with two equally serious concurrent conditions, such as lower urinary tract disease and obesity. Our new Multifunction diets do just this.
"Pets suffering from more than one condition also generally require more regular veterinary care, too, and a unique new ordering system for these diets helps facilitate ongoing contact between the pet owner and their veterinary practice every time they order a new bag of food. More information about the diets and the ordering system will be available on the ROYAL CANIN, stand: 611."
Multifunction will only be available through veterinary practices and all bags will be personalised, including the practice logo and patient name. Further information on how to sign up to the product programme will be available at the show stand.
For more information, visit: http://new.vetportal.royalcanin.co.uk/products/multifunction-2/
55 veterinary surgeons took part in the survey, which also found that only 37% of clinicians use FNA and cytology when investigating a suspected lipoma.
According to the survey, the biggest barriers to further investigations of lumps and bumps were cost (50%), short consult time (23%) and confidence in results (20%).
HT Vista, which earlier this year launched a cancer screening device for dogs which uses heat diffusion technology and AI to differentiate between benign skin masses and other tumours, is urging more practising vets to use an accurate screening process for early detection of malignant masses.
Dr. Gillian Dank, Board Certified Oncologist and Chief Veterinary Officer at HTVet, said: “There is no way to know that a mass is a lipoma based on palpation alone.
"The fact that a mass is subcutaneous, soft and circumscribed is not exclusive to lipoma and it could be a number of things including a mast cell tumour or sarcoma.
"On average a veterinary practice sees over 500 dermal and subcutaneous masses each year.
"We know anecdotally, and surveys like this confirm, that not every mass is aspirated – and that is why there is need for the HT Vista screening device.
"Every mass that comes in should be properly examined.”
“It’s interesting to see that the more experienced a clinician is, the less confident they are in diagnosing from palpation and this shows us that with experience we understand that our hands are not enough.”
Liron Levy-Hirsch, Managing Director of HT Vista, said: “The survey showed that vets are conscious of the cost to clients, and also feel pressured due to time.
"We have developed the HT Vista to complement FNA and cytology, and hope clinicians find it a useful tool.
"Firstly, it is quick and affordable to scan, and for those masses that are benign it removes the need for unnecessary FNA’s.
"Secondly, vets are often wary of cost, however if a mass is scanned and the results indicate that further investigation is needed, there is more rationale to spend the extra money to get the cytology results.
"Finally, the device can offer complete confidence that malignancies are not being missed, and if a mass is malignant a prompt treatment plan can be initiated.”
https://www.vetreport.net/wp-content/uploads/2023/08/Lump-and-Bump-Survey-2023FINAL.pdf
https://ht-vista.uk